Reston, VA— A new supplement to The Journal of Nuclear Medicine shines a spotlight on the role China has played in advancing global nuclear medicine, with an eye to the country’s future contributions. The supplement details significant advances in research and development, as well as the clinical translation of novel radiopharmaceuticals, and aims to inform and inspire future international collaborations and multicenter studies.
“Research and innovation do not adhere to global borders, and tremendous innovation in our field has been recently initiated in China,” said Johannes Czernin, MD, JNM Editor-in-Chief. “This supplement features the impressive basic research and clinical translation taking place in China and will be of interest not only to the academic nuclear medicine and theranostics community, but also to professionals in the fields of oncology and translational research, as well as in the pharmaceutical and medical device industries.”
The supplement has three areas of focus: long-field PET scanners, new theranostic approaches, and the nuclear medicine regulatory landscape in China. In the first area of focus, pioneering clinical work with long-field PET scanners and their role in drug development is discussed. The second focus, exploring the new wave of innovative theranostic concepts, includes articles discussing FAPI, nectin-4, and melanin-targeting efforts. The third focus, the regulatory landscape, covers the pathways to approval of innovative radiopharmaceuticals in China.
Led by an international team of editors including Wolfgang Weber, MD, PhD; Haojun Chen, MD; Kuangyu Shi, PhD; Weibo Cai, PhD; and Ken Herrmann, MD, this supplement features top experts in the fields of molecular imaging and theranostics in China. Articles include:
The JNM Molecular Imaging of Neurodegeneration Supplement is available at https://jnm.snmjournals.org/content/65/Supplement_1 .
Visit the JNM website for the latest research, and follow our Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org .
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 14 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org .
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org .
Journal of Nuclear Medicine
1-May-2024